FibroGen Inc (FGEN)

FibroGen Inc (FGEN) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Jan 9, 2026: market cap $39.3M; returns 1 week +0.7%.

FibroGen Inc., which rebranded to Kyntra Bio in January 2026, is a clinical-stage biopharmaceutical company that has undergone a massive strategic pivot following the late-2024 failure of its lead candidate, pamrevlumab, in pancreatic cancer. The company's economic model shifted from a broad fibrosis and anemia focus to a concentrated oncology and rare disease strategy.

FGEN financial model: income statement, cash flow and balance sheet